Adamas Pharma (ADMS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
8.22 +0.06 (+0.74%) 11/23/21 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 8.22 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -57,403 | -105,186 | -130,999 | -89,490 | -60,058 |
| Depreciation Amortization | 716 | -5 | 415 | 1,650 | 507 |
| Accounts receivable | -2,272 | -259 | -5,144 | 427 | 490 |
| Accounts payable and accrued liabilities | -4,979 | 398 | 2,759 | 333 | 502 |
| Other Working Capital | -15,200 | -5,173 | -9,754 | 3,295 | 912 |
| Other Operating Activity | 28,430 | 29,446 | 38,500 | 16,958 | 9,579 |
| Operating Cash Flow | $-50,708 | $-80,779 | $-104,223 | $-66,827 | $-48,068 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 37,874 | 88,881 | -68,274 | 26,823 | -25,085 |
| PPE Investments | N/A | -18 | -1,064 | -1,258 | -1,624 |
| Sale Of Investment | 17,066 | 0 | N/A | N/A | N/A |
| Investing Cash Flow | $54,940 | $88,863 | $-69,338 | $25,565 | $-26,709 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,650 | N/A | N/A | N/A | N/A |
| Debt Issued | N/A | N/A | 0 | 99,600 | 0 |
| Common Stock Issued | 1,217 | 310 | 137,613 | 9,110 | 64,788 |
| Other Financing Activity | -2,213 | 775 | 1,237 | 133 | 620 |
| Financing Cash Flow | $1,654 | $1,085 | $138,850 | $108,843 | $65,408 |
| Beginning Cash Position | 65,774 | 56,605 | 91,316 | 23,735 | 33,104 |
| End Cash Position | 71,660 | 65,774 | 56,605 | 91,316 | 23,735 |
| Net Cash Flow | $5,886 | $9,169 | $-34,711 | $67,581 | $-9,369 |
| Free Cash Flow | |||||
| Operating Cash Flow | -50,708 | -80,779 | -104,223 | -66,827 | -48,068 |
| Capital Expenditure | 0 | -18 | -1,064 | -1,258 | -1,624 |
| Free Cash Flow | -50,708 | -80,797 | -105,287 | -68,085 | -49,692 |